SCHEMBL5424070

SCHEMBL5424070

Cc1onc(-c2ccccc2)c1-c1ccc(C(=O)O)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 10/20 0.57
▸ PTGS1 P23219 7/20 0.57
▸ MT-CO2 P00403 3/20 0.52
▸ LMNA P02545 2/20 0.51
▸ CA12 O43570 1/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ CA3 P07451 1/20 0.51
▸ ADRB2 P07550 1/20 0.51
▸ ADRB1 P08588 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ ADORA3 P0DMS8 1/20 0.51
▸ CHRM1 P11229 1/20 0.51
▸ ADRA2B P18089 1/20 0.51
▸ CA4 P22748 1/20 0.51
▸ CA6 P23280 1/20 0.51
▸ SLC6A2 P23975 1/20 0.51
▸ PDE4A P27815 1/20 0.51
▸ ADORA1 P30542 1/20 0.51
▸ CA5A P35218 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14562102 0.87 PTGS2 (0.60) PTGS2PTGS1MT-CO2LMNACA12
SCHEMBL5423393 0.82 GABRA5 (0.50) PTGS2PTGS1MT-CO2KDM4EHTT
SCHEMBL14562118 0.82 KDM4E (0.48) PTGS2PTGS1MT-CO2LMNACA12
SCHEMBL14562104 0.80 PTGS2 (0.57) PTGS2PTGS1MT-CO2LMNACA12
SCHEMBL14562171 0.79 PTGS2 (0.64) PTGS2PTGS1MT-CO2LMNACA12
SCHEMBL5420970 0.79 PTGS2 (0.56) PTGS2PTGS1MT-CO2LMNACA12
SCHEMBL14562116 0.78 GAA (0.48) PTGS2PTGS1MT-CO2KDM4EHTT
SCHEMBL5428461 0.78 PTGS2 (0.73) PTGS2PTGS1MT-CO2LMNACA12
SCHEMBL5439437 0.78 PTGS2 (0.73) PTGS2PTGS1MT-CO2LMNACA12
SCHEMBL5436667 0.76 KMT2A (0.53) PTGS2PTGS1MT-CO2LMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060629-A1 Large conductance calcium-activated k channel opener TANABE SEIYAKU CO., LTD. (JP) 2007-03-15 — — US disclosed
US-20070060629-A1 Large conductance calcium-activated k channel opener TANABE SEIYAKU CO., LTD. (JP) 2007-03-15 — — US disclosed
US-20070060629-A1 Large conductance calcium-activated k channel opener TANABE SEIYAKU CO., LTD. (JP) 2007-03-15 — — US disclosed
EP-1675585-A2 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER TANABE SEIYAKU CO., LTD. (JP) 2006-07-05 — — EP disclosed
WO-2005037271-A2 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER TANABE SEIYAKU CO., LTD. (JP) 2005-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060629-A1 Large conductance calcium-activated k channel opener KCNN3, KCNN1, KCNN2 PTGS2 594/4885PTGS1 558/4885MT-CO2 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback